Stock 603896 ZHEJIANG SHOUXIANGU PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

Equities

603896

CNE100002XJ4

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-15 pm EDT 		5-day change 1st Jan Change
22.6 CNY -0.26% Intraday chart for Zhejiang Shouxiangu Pharmaceutical Co., Ltd. +1.07% -29.90%
Jul. 12 Shouxiangu Pharmaceutical Gets Patent for Chinese Medicine Composition MT
Apr. 25 Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Shouxiangu Pharmaceutical Gets Patent for Chinese Medicine Composition
MT
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.(XSSC:603896) added to S&P Global BMI Index
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. agreed to acquire Hangzhou Yunhe Hengli Commercial Real Estate Co., Ltd from Hangzhou Yunhe Group Construction Management Co., Ltd. for CNY 0.001 million.
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Shouxiangu Pharma Unit Secures Re-Registration Approval for Three Drugs
MT
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 4, 2020, has expired with 3,585,000 shares, representing 2.5% for CNY 165.08 million.
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Tranche Update on Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 4, 2020.
CI
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603896 Stock
  4. News Zhejiang Shouxiangu Pharmaceutical Co., Ltd.